Followers | 36 |
Posts | 2,689 |
Boards Moderated | 0 |
Alias Born | 06/09/2011 |
Twitter Profile: | Temporarily Unavailable |
Follow on Twitter: | Follow @ Temporarily Unavailable |
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Great post Jack and so well stated thanks for sharing your thoughts as this is in line with mine.
Great find Lykiri and I found CEO's quote interesting and positive as he obviously is speaking about NWBO and DCVax-L.
It states Not FDA Approved for Orphan Indication?
Great post Senti and so well said!
Great call reversing looking like move to being green this afternoon
Great volume today 2.7M traded! Up 20% for the day so far!
L2 great volume out of the open great to see!!!
Slow steady accumulation going on the past couple of weeks IMHO
Great post Abeta!! Very telling!!
DCVax: A Promising New Treatment for Glioblastoma
By Samuel Sachs -June 6, 2018
HEALTH + BEHAVIOR
Personalized vaccine may increase long-term survival in people with deadliest form of brain cancer
UCLA-led study evaluates treatment using a person’s own white blood cells
Denise Heady | June 05, 2018
Neuroscience News and Research
Yesterday at 4:01am ·
Promising!
https://www.facebook.com/NeuroNewsResearch/posts/1946857315333017
Great post and well said!
Thanks Tadasana! There are so many outstanding contributors to this board you cant even list them all.
It has been a very long road for NWBO but I think we are finally approaching the finish line pretty soon, IMHO! I have been in and out of NWBO since 2008 and have continued to accumulate a lot of this stock lowering my cost basis to $.32 and wish all longs and patients a successful regulatory approval of the DCVax platform for inoperable and operaple solid tumors!
Yes I agree with you very interesting article especially with Dr. Liau comments.
Not sure if this was posted yet from yesterday....
Article now in Iran today as news media around world picking up this story!
http://www.iran-daily.com/News/216055.html
Yes Asta that also was nice to see as well as the results summary highlight just above her comments. Impressive data
Cancer vaccine may increase survival in patients with deadly brain cancer
All Specialities, Latest News, Medicine, NeurosciencesMay 31, 2018
Worth a read!!!
https://speciality.medicaldialogues.in/cancer-vaccine-may-increase-survival-in-patients-with-deadly-brain-cancer/
Brain Cancer Vaccine Effective in Some Patients
Neuroscience NewsNEUROSCIENCE NEWSMAY 31, 2018
The Journal article and NWBO press release are hitting countries media outlets all over the world including Russia.
News hitting China now.....
http://www.china.org.cn/world/Off_the_Wire/2018-05/31/content_51542295.htm
Yes that is excactly how I interpreted it when I read it a few times.
Kat's Story published in Sweden today.....
The vaccine saved the life of the cancer victim mum
published May 30, 2018 at 19.00
NEWS RELEASE
Brain cancer vaccine effective in some patients
Personalized vaccine may extend survival of glioblastoma patients
by Julia Evangelou Strait•May 29, 2018
Very good volume today way above 10 day and I have not had opportunity to check it out today. Any update appreciated! Thank you.
Great points highlighted in this post Flip!
Just speculating but EAP trial has a Boston location.
United States, Massachusetts
Beth Israel Deaconess Medical Center
Boston, Massachusetts, United States, 02215
Contact: Emma Breault 617-667-5984 ebreault@bidmc.harvard.edu
Principal Investigator: David Avigan, MD
Brain Tumor Vaccine
By admin On December 20, 2017
So very well said! Thanks for sharing and in agreement with you 100%!
Journal of Neurology
pp 1–16 | Cite as
Advances in immunotherapeutic research for glioma therapy
Authors
Authors and affiliations
Jeremy Tetsuo MiyauchiStella E. TsirkaEmail author
1.
Review
First Online: 05 December 2017
https://link.springer.com/article/10.1007/s00415-017-8695-5
Great post and well stated!
Sojourner...thanks for sharing your TA as I personally look forward to your charts.
Health
New Report Shares Details about Dendritic Cell Cancer Vaccine Market by 2025
**Northwest Bio listed at bottom of this release**
Dendritic cells (DCs) are one of the major antigen-presenting cells found in lymphoid organs. Main function of the dendritic cells is antigen display and activation of T-cells. Antigen display presents the identity of pathogen to T-cells for their identification and elimination from the body. These cells have proficiency of capturing and processing tumor antigens, which activates expression of lymphocyte co-stimulatory molecules. Consequently, it results in secretion of cytokines to initiate immune response. In 1868, Paul Langerhans discovered dendritic cells. He thought they were a part of the nervous system cells due to their branched structure. Therefore, their identity was mistaken until the 1970s. In 1973, Zanvil Cohn and Ralph Steinman recognized them as a new type of white blood cells (WBC) with distinctive nature, features, concentration, and function in immunity.
Cancer is an enormously complex disease and researchers are still trying to understand the variety of factors responsible for its origin, transmission, metastasis, etc. According to report on cancer vaccines by the World Health Organization (WHO), in 2016, an anticipated 1.7 Mn new cancer cases were reported in the U.S. alone. Furthermore, the report mentioned that the annual incidence of cancer, worldwide, is projected to increase to 24 Mn by 2035. Presently, there is significant requirement for advanced and efficient treatments for cancer. Current standard approaches include radiation therapy, chemotherapy, and surgery. However, there are some risks and side effects associated with these methods. Different kinds of cancers have various sources of origin and have unique mechanisms which presents different complications in front of researchers to develop wide-ranging therapeutic treatments. Dendritic cells are adaptable in nature. Therefore, they can be modified depending on the cancer under examination, a dendritic cells vaccine can be formulated based on type of tumor accompanying antibodies. This vaccine can be expressed to target multiple cancers, which makes them effective for multiple objectives. Many of the clinical trials are investigating dendritic cell cancer vaccines which has the ability to help numerous patients. Currently, a steady supply of dendritic cells is necessary to develop novel cancer vaccines. Genetically modified dendritic cell cancer vaccines are grander tools for directing intractable cancers such as brain cancer therapy.
Many studies have shown dendritic cells have the potential ability in combinational therapies to restrict the growth of the cancer. The assured curable effect of therapeutics, which also includes these vaccines, has not been proven; however, they are anticipated to perform far better than its contenders in the same category. The rise in investments in research and development activities, together with positive results in clinical trials, are anticipated to drive the expansion of the market for global dendritic cell cancer vaccine. Others factors fuelling the expansion of this market include the ability of dendritic cells to target multiple cancer antigen capability, rise in geriatric population, and technological advancements. Computer technology is assisting oncologists to plan and run replications on hypothetical vaccines to check their consequences on cellular forms, before going to lab tests and utilizing costly resources.
However, the results of dendritic cell cancer vaccines remain mysterious in clinical trials. More than 70% of these vaccine candidates are currently in clinical trial phases of development. The global dendritic cells vaccines market has accomplished to capture the attention of many strategic investors and stakeholders due to a lucrative development in pipeline. More than USD 1.5 billion has already been invested in this area in the last five years. Oncologists believe that this market is likely to present considerable lucrative opportunities due to existing unmet demand for safe and effective cancer treatments with less side effects and the innate advantages of dendritic cells.
Currently, the three marketed cancer vaccines commercially available in different geographies are Provenge (U.S.), CreaVax-RCC (South Korea), and Tumor Antigen Presenting Cells i.e. TAPCells (Chile). Provenge, is the first marketed dendritic cell vaccine available in the market. They are targeted to treat prostate cancer, metastatic renal cell carcinoma, melanoma, and prostate cancer. In April 2010, the FDA approved the first cancer treatment vaccine. This vaccine, sipuleucel-T (Provenge), is approved for usage in some men with metastatic prostate cancer.
Request for Report ToC: www.transparencymarketresearch.com/sample/sample.php?flag=T&rep_ ..
Key players operating in this market include 3M Company, Batavia Bioservices, Activartis, Dendreon, Merck KGaA, GlaxoSmithKline plc, Northwest Biotherapeutics, Tella Incorporation, Creagene, and ImmunoCellular Therapeutics.
Press Information
Published by
Abhishek Budholiya
+1-347-918-3531
e-mail
www.futuremarketinsights.com
https://www.pr-inside.com/new-report-shares-details-about-dendritic-cell-can-r4655018.htm
CLSN another good volume day with over 2.8M shares traded and PPS up 18+%...obviously following large volume trading last Friday afternoon.
Great post Flip! So very well said and agree with you 100%!
What is up with the large uptick in volume and PPS in the last 30 minutes??
Hedge fund Kerrisdale shorts Woodford's Prothena stock
News
10 NOV 2017
US hedge fund Kerrisdale has launched a short-selling attack on Prothena (PRTA.O), the top holding in the Woodford Patient Capital(WPCT) investment trust.
Northwest Bio mentioned in this article....
Within biotechnology, Woodford is best known for buying a 28 per cent stake in Northwest Biotherapeutics, a company alleged to have engaged in a paid stock-promotion scheme and currently under Securities and Exchange Commission investigation.‘The stock has declined by more than 95 per cent and Woodford’s stake – originally purchased for [over] $150 million, is now virtually worthless,’ Kerrisdale claims.
http://www.whatinvestment.co.uk/kerrisdale-shorts-woodford-stock-prothena-2554561/
Great post Flip and agree with your assumptions